Hjem › Myelofibrose › Pennsylvania
Myelofibrose kliniske forsøg i Pennsylvania
8 studier for Myelofibrose søger deltagere på steder i Pennsylvania.
Byer i Pennsylvania
Officiel studietekst (engelsk)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office, Philadelphia
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07469891A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Thomas Jefferson University, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- Allegheny Health Network Cancer Institute - West Penn Hospital Location, Pittsburgh
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07623161Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- University of Pennsylvania, Philadelphia
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT05320198A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- UPMC Hillman Cancer Center ( Site 6004), Pittsburgh
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. apr. 2026 · NCT06351631Two Step Haplo With Radiation Conditioning
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. okt. 2025 · NCT05031897SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- West Penn Hospital, Pittsburgh
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT06479135Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
- Fox Chase Cancer Center - Philadelphia, Philadelphia
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 3. maj 2024 · NCT06218628Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.